Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H29N3O5.ClH |
Molecular Weight | 403.901 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C
InChI
InChIKey=LBARATORRVNNQM-UHFFFAOYSA-N
InChI=1S/C18H29N3O5.ClH/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7;/h8-10,15,19,22H,11H2,1-7H3;1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H29N3O5 |
Molecular Weight | 367.44 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24277179Curator's Comment: Description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24277179
Curator's Comment: Description was created based on several sources, including
https://www.medicines.org.uk/emc/medicine/9574 | http://www.meppo.com/pdf/drugs/2596-BAMBEC-ORAL-SOLUTION-1427211370.pdf | https://www.ncbi.nlm.nih.gov/pubmed/2906603
Bambuterol is an active precursor of the selective beta2-adrenergic agonist terbutaline. Bambuterol is the bis-N,N-dimethyl-carbamate of terbutaline.
Bambuterol is a remarkably selective and potent inhibitor of cholinesterase. BAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24277179
Curator's Comment: # AB Draco (Subsidiary of AB Astra, now AstraZeneca)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.medicines.org.uk/emc/medicine/9574 |
|||
Target ID: CHEMBL1914 |
17.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BAMBEC Approved UseBAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction. |
|||
Primary | BAMBEC Approved UseBAMBEC (Bambuterol hydrochloride) oral solution or tablets are indicated for the management of asthma, bronchospasm and/or reversible airways obstruction. |
PubMed
Title | Date | PubMed |
---|---|---|
Tremor in healthy volunteers after bambuterol and terbutaline CR-tablets. | 1993 |
|
Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. | 1993 Nov |
|
Can oral beta2 agonists cause heart failure? | 1998 Oct 3 |
Patents
Sample Use Guides
BAMBEC (Bambuterol hydrochloride) Tablets 10 mg. The recommended starting doses are 10 mg–20 mg. The 10 mg dose may be increased to 20 mg if necessary after 1–2 weeks, depending on the clinical effect. In patients who have previously tolerated beta2-agonists well, the recommended starting dose, as well as maintenance dose, is 20 mg.
BAMBEC (Bambuterol hydrochloride) oral solution 1mg/ml. The recommended initial dose is 10mg (10ml). The dose may be increased to 20mg (20ml) after 1-2 weeks, depending on the clinical effect. In patients who previously have tolerated oral beta2-agonists well, the recommended initial dose is 20mg (20ml).
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:18:28 GMT 2023
by
admin
on
Fri Dec 15 17:18:28 GMT 2023
|
Record UNII |
786Q84QZ3F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
54765
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
DB01408
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
DTXSID8045515
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
81732-46-9
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
786Q84QZ3F
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
100000092785
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
235862
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
59167
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
758916
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
C047766
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | |||
|
m2216
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB00659MIG
Created by
admin on Fri Dec 15 17:18:28 GMT 2023 , Edited by admin on Fri Dec 15 17:18:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |